Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation

Mahmoud M. Iravani, Peter Jenner

Research output: Contribution to journalLiterature reviewpeer-review

64 Citations (Scopus)

Abstract

A significant proportion of patients with Parkinson's disease (PD) receiving dopamine replacement therapy in the form of levodopa develop dyskinesia that becomes a major complicating factor in treatment. Dyskinesia can only be effectively treated by a reduction in drug dose, which limits efficacy, by co-administration of the weak NMDA antagonist amantadine or by surgical treatment (pallidotomy, DBS). This raises the important question of why dyskinesia occurs in PD and how it can be avoided or suppressed by pharmacological treatment. This review assesses some of the mechanisms that underlie dyskinesia induction and expression from presynaptic changes in dopaminergic neurones to postsynaptic alterations in basal ganglia function and examines potential approaches to prevention and treatment. These include glutamatergic approaches where agents that directly or indirectly alter glutamatergic neurotransmission modify the intracellular influx of Ca2+ and reduce the formation of nitric oxide by neuronal nitric oxide synthase that may form an integral component of the complex cascade of events leading to dyskinesia. There is increasing evidence for the role of serotoninergic neurones in dyskinesia induction related to non-physiological formation and release of dopamine and serotoninergic agonists can modify dyskinesia expression. Similarly, noradrenergic receptors may serve to alter dyskinesia intensity and alpha-2-adrenoceptor antagonists alter the expression of levodopa-induced dyskinesia in both experimental models of PD and in man. Finally, other potential approaches to dyskinesia treatment based on manipulation of opiate, cannabinoid, adenosine and histamine receptors are considered. The conclusion is that the cause of levodopa-induced dyskinesia remains to be fully elucidated and that new approaches to treatment through non-dopaminergic mechanisms are required to control the onset and expression of involuntary movements.

Original languageEnglish
Pages (from-to)1661-1690
Number of pages30
JournalJournal of Neural Transmission
Volume118
Issue number12
DOIs
Publication statusPublished - Dec 2011

Keywords

  • Levodopa
  • Parkinson's disease
  • Dyskinesia
  • Presynaptic mechanisms
  • Postsynaptic mechanisms
  • DOPA-INDUCED DYSKINESIA
  • METABOTROPIC GLUTAMATE RECEPTORS
  • NITRIC-OXIDE SYNTHASE
  • INDUCED MOTOR COMPLICATIONS
  • TREATED COMMON MARMOSETS
  • ADENOSINE A(2A) RECEPTORS
  • CANNABINOID CB1 RECEPTOR
  • IN-SITU HYBRIDIZATION
  • IDIOPATHIC PARKINSONS-DISEASE
  • MESSENGER-RNA EXPRESSION

Fingerprint

Dive into the research topics of 'Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation'. Together they form a unique fingerprint.

Cite this